XML 17 R4.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Consolidated Statements of Operations [Abstract]    
Revenues $ 35,283,868 $ 22,487,566
Cost of revenues 31,136,129 20,158,828
Research and development 15,108,528 23,899,026
Impairment of goodwill and intangible assets 0 62,273,336
Selling, general, and administrative 20,374,969 30,005,542
Operating expenses 66,619,626 136,336,732
Operating loss (31,335,758) (113,849,166)
Other income (expense):    
Other income (expense), net 21,957 17,723,579
Interest expense (1,857,694) (2,128,442)
Other income (expense) total (1,835,737) 15,595,137
Loss before provision (benefit) for income taxes and noncontrolling interests (33,171,495) (98,254,029)
Provision (benefit) for income taxes 138,038 (17,243,528)
Net loss (33,309,533) (81,010,501)
Less - loss attributable to noncontrolling interests (653,214) (124,549)
Net loss attributable to Caladrius Biosciences, Inc. common stockholders $ (32,656,319) $ (80,885,952)
Basic and diluted (loss) per share attributable to:    
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders (in dollars per share) $ (4.99) $ (16.67)
Weighted average common shares outstanding (in shares) 6,548,251 4,850,811